Ranitidine: Resolved

In 2019, Mylan issued a pharmacy-level recall of all batches of Ranitidine Relief 150 mg and 300 mg tablets and GlaxoSmithKline issued a recall of all batches of Zantac inj 25 mg per ml, 2ml in in New Zealand.

 This recall was part of a global recall of all brands and presentations of ranitidine.

Ranitidine is no longer being manufactured. PHARMAC will delist Ranitidine Relief from the Pharmaceutical Schedule from 1 October 2020 and Zantac will be delisted in 2021.

Alternative funded treatments

BPACnz have advice on managing gastro-oesophageal reflux disease (GORD) in adults which may be helpful when considering alternative treatment options.

H2 antagonists 

Ranitidine is a type of medicine called an H2 antagonist. PHARMAC has secured a supply of famotidine as an alternative.

Please note that Famotidine Hovid has not been approved by Medsafe, so it will need to be supplied under Section 29 of the Medicines Act 1981.

Proton pump inhibitors

Our clinical advice is that some patients may be able to be transitioned to a proton pump inhibitor.

Who to contact

For more information about the recall, contact Mylan on 0800 579 811.